Abvc Biopharma Stock Analysis

ABVC Stock Analysis Notes

The book value of the company was presently reported as 0.51. The company recorded a loss per share of 0.28. ABVC Biopharma last dividend was issued on the 8th of May 2019. The entity had 1:10 split on the 25th of July 2023. ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation. Abvc Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on ABVC Biopharma please contact Howard MD at 510 668 0881 or go to https://www.abvcpharma.com.

ABVC Biopharma Investment Alerts

ABVC Largest EPS Surprises

View All Earnings Estimates

ABVC Stock Institutional Investors

Note, although ABVC Biopharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

ABVC Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 46.17 M.

ABVC Profitablity

Management Efficiency

ABVC Biopharma has return on total asset (ROA) of (0.1722) % which means that it has lost $0.1722 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4771) %, meaning that it created substantial loss on money invested by shareholders. ABVC Biopharma's management efficiency ratios could be used to measure how well ABVC Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of February 5, 2026, Return On Tangible Assets is expected to decline to -0.79. In addition to that, Return On Capital Employed is expected to decline to -5.78. At present, ABVC Biopharma's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 10.7 M, whereas Total Current Assets are forecasted to decline to about 1.3 M.

Technical Drivers

As of the 5th of February, ABVC Biopharma shows the Mean Deviation of 3.07, variance of 15.17, and Market Risk Adjusted Performance of (0.79). ABVC Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.

ABVC Biopharma Price Movement Analysis

ABVC Biopharma Insider Trading Activities

ABVC Biopharma Outstanding Bonds

ABVC Biopharma Predictive Daily Indicators

ABVC Biopharma Forecast Models

ABVC Biopharma's time-series forecasting models are one of many ABVC Biopharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ABVC Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

ABVC Biopharma Bond Ratings

ABVC Biopharma financial ratings play a critical role in determining how much ABVC Biopharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for ABVC Biopharma's borrowing costs.

ABVC Biopharma Debt to Cash Allocation

ABVC Biopharma currently holds 3.2 M in liabilities with Debt to Equity (D/E) ratio of 0.34, which is about average as compared to similar companies. ABVC Biopharma has a current ratio of 2.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ABVC Biopharma's use of debt, we should always consider it together with its cash and equity.

ABVC Biopharma Total Assets Over Time

ABVC Biopharma Assets Financed by Debt

The debt-to-assets ratio shows the degree to which ABVC Biopharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

ABVC Biopharma Debt Ratio

46.0

It looks as if about 54% of ABVC Biopharma's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the ABVC Biopharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of ABVC Biopharma, which in turn will lower the firm's financial flexibility.

ABVC Biopharma Corporate Bonds Issued

ABVC Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how ABVC Biopharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ABVC shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ABVC Biopharma. By using and applying ABVC Stock analysis, traders can create a robust methodology for identifying ABVC entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ABVC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ABVC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

ABVC Biopharma stock analysis indicators help investors evaluate how ABVC Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ABVC Biopharma shares will generate the highest return on investment. By understating and applying ABVC Biopharma stock analysis, traders can identify ABVC Biopharma position entry and exit signals to maximize returns.

When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.